Market Cap: $1.25B
OC
Omeros Corporation
OMER
NASDAQ (NASDAQ Global Market)USD
Market Cap: $1.25B
Omeros Corporation (Ticker: OMER) shows strong initial performance for its recently launched drug YARTEMLEA, indicating a promising trajectory for the company. In its Q1 2026 earnings report, Omeros a…
It appears that there is no specific content provided for me to summarize. If you could share the text or details about Omeros or relevant developments in the industry, I'd be glad to assist in creati…
Omeros Advances in Therapeutic Development Amid Economic Uncertainty Omeros Corporation makes significant strides in the biopharmaceutical sector as it focuses on advancing its therapeutic pipeline. T…
Omeros Corporation Gains FDA Approval for Yartemlea: A Breakthrough in Treating TA-TMA Omeros Corporation achieves a significant milestone with the U.S. Food and Drug Administration's (FDA) approval o…
Omeros Corporation Secures FDA Approval for Yartemlea in Treating TA-TMA Omeros Corporation achieves a significant milestone with the recent approval of Yartemlea (narsoplimab-wuug) by the U.S. Food a…
Omeros Achieves Milestone with FDA Approval of Yartemlea for TA-TMA Treatment Omeros Corporation celebrates a pivotal achievement with the recent approval of its drug Yartemlea (narsoplimab-wuug) by t…
Omeros Corporation Advances in Therapeutic Innovations Amid Market Volatility Omeros Corporation continues to make significant strides in the field of therapeutic innovations, particularly in the deve…
Omeros Advances in Therapeutic Development Amid Market Fluctuations Omeros Corporation, a biopharmaceutical company known for its innovative treatments, continues to make significant strides in the de…
Omeros Corporation Advances in Therapeutic Development Amid Economic Uncertainty Omeros Corporation, a biopharmaceutical company specializing in developing innovative therapeutics, continues to forge…
Omeros Advances in Therapeutic Innovation Amid Industry Developments Omeros Corporation stands at the forefront of therapeutic innovation, particularly in the field of immunology and inflammation. The…
Omeros Prepares for Key Quarterly Earnings Announcement Amidst Pipeline Developments As Omeros Corporation approaches its quarterly earnings announcement scheduled for November 13, 2025, the biopharma…
Omeros Corporation: Pioneering Innovations in Rare Disease Therapies Omeros Corporation stands at the forefront of the biotechnology revolution, particularly in the field of rare diseases. The company…
Omeros Corporation: Pioneering Innovations in Rare Disease Therapies Omeros Corporation stands at the forefront of the biotech industry, driving innovative solutions for rare diseases. The company is…
Omeros Corporation: Pioneering Innovations in Immune Regulation Omeros Corporation is at a critical juncture as it prepares to release its quarterly earnings report on August 14, 2025. Central to its…
Omeros Corporation: Driving Innovation in Biotech with Promising Therapeutic Solutions Omeros Corporation stands at the forefront of biopharmaceutical innovation, focusing on the development of novel…
Omeros Corporation: A Promising Future in Biotech Innovation Omeros Corporation is gaining attention in the biotech industry due to its innovative therapeutic solutions targeting neurology and inflamm…
Omeros Corporation's Breakthrough Presentations on Narsoplimab at 2025 Tandem Meetings Omeros Corporation is set to showcase significant advancements in the treatment of hematopoietic stem cell transp…
Omeros Corporation Validates Narsoplimab's Efficacy in Treating TA-TMA Omeros Corporation, a leader in monoclonal antibody development, announces compelling results from a comprehensive statistical se…
Omeros Advances Treatment for Paroxysmal Nocturnal Hemoglobinuria with Zaltenibart Omeros Corporation has made significant strides in developing its investigational drug zaltenibart (OMS906) for treat…
Omeros Advances MASP-3 Inhibition with Promising Data on Zaltenibart for PNH Treatment Omeros Corporation recently garners attention at the 66th Annual Meeting of the American Society of Hematology (A…
Omeros Advances Zaltenibart for PNH Treatment Ahead of ASH Conference Omeros Corporation is set to showcase its investigational drug, zaltenibart (OMS906), at the upcoming 66th Annual Meeting of the A…
Omeros Advances Narsoplimab BLA Resubmission Efforts Amid FDA Feedback Omeros Corporation is currently making significant strides in the resubmission process for its biologics license application (BLA…
Omeros Corporation Charts a Path Forward with Narsoplimab and Zaltenibart Omeros Corporation continues to make significant strides in the development of its therapies, particularly focusing on narsopl…
Omeros Corporation Advances Its Therapeutic Pipeline with Regulatory Engagements Omeros Corporation, a biopharmaceutical company focused on innovating therapeutics for complex diseases, announces sign…